MAGEC2
MAGEC2 (MAGE family member C2, also known as CT10, MAGE-C2, HCA587 and MAGEE1) is a cancer/testis antigen of the MAGE family. It is proposed to enhance the activity of RING-type E3 ubiquitin ligases, including TRIM28. Browse Assay Genie's current range of MAGEC2 research reagents below, or read on for the biology behind the target.
MAGEC2 is proposed to enhance the ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro, it increases the activity of TRIM28 and stimulates ubiquitination of p53/TP53 in the presence of the Ubl-conjugating enzyme UBE2H, which leads to p53/TP53 degradation. It is thought to act by recruiting and/or stabilising the Ubl-conjugating enzymes (E2) at the E3:substrate complex. The protein is found in the cytoplasm and the nucleus.
The MAGEC2 gene belongs to the MAGEC gene family, within the wider MAGE family. According to the NCBI Gene summary, it is not expressed in normal tissues except for testis, and it is expressed in tumours of various histological types. This restricted pattern is the reason it is classed as a cancer/testis antigen. MAGEC2 and the other MAGEC genes, such as MAGEC1, are clustered on the X chromosome.
MAGEC2 has been catalogued under several names. These include CT10, MAGE-C2, HCA587 and MAGEE1, and the earlier HGNC names 'melanoma antigen, family E, 1, cancer/testis specific' and 'melanoma antigen family C2'. Researchers studying tumour-restricted antigens, p53 regulation or ubiquitin ligase activity may therefore find MAGEC2 relevant to their work, whether they use a MAGEC2 antibody, a MAGEC2 protein or an expression assay.
MAGEC2 is absent from normal tissue except testis but is expressed in tumours of various histological types, making it a model for tumour-restricted expression.
MAGEC2 is proposed to enhance RING-type E3 ligase activity, including TRIM28, by recruiting or stabilising E2 conjugating enzymes.
In vitro, MAGEC2 with TRIM28 and UBE2H stimulates p53/TP53 ubiquitination, leading to its degradation.
MAGEC2 is clustered with other MAGEC genes on the X chromosome, supporting comparative work across the MAGEC family.
MAGEC2 is proposed to enhance the activity of RING-type E3 ubiquitin ligases. In vitro it boosts TRIM28 activity and, with UBE2H, stimulates p53/TP53 ubiquitination and degradation. It may act by recruiting or stabilising E2 enzymes at the E3:substrate complex.
MAGEC2 is also called CT10, MAGE-C2, HCA587 and MAGEE1. Earlier names include 'melanoma antigen, family E, 1, cancer/testis specific' and 'melanoma antigen family C2'. UniProt lists the protein as melanoma-associated antigen C2.
The NCBI Gene summary states that MAGEC2 is not expressed in normal tissues except testis, and that it is expressed in tumours of various histological types. Check the datasheet of any product for its validated reactivity.
Other MAGEC family members that are clustered with MAGEC2 and share its cancer/testis expression pattern.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9UBF1; product specifications from Assay Genie datasheets.